ECB-ART-50001
J Thorac Dis
2016 Sep 01;89:E1028-E1031. doi: 10.21037/jtd.2016.09.09.
Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases.
Guo J
,
Zinner R
,
Zaorsky NG
,
Guo W
,
Lu B
.
Abstract
PubMed ID:
27747054
PMC ID:
PMC5059245
Article link:
J Thorac Dis
References [+] :
Barlesi,
Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01).
2011,
Pubmed
Barlesi,
Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01).
2011,
Pubmed
Costa,
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
2015,
Pubmed
Gerstner,
Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm.
2007,
Pubmed
Guérin,
Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
2015,
Pubmed
Kim,
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
2016,
Pubmed
Lee,
Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
2005,
Pubmed
Lee,
Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first : result of a randomized pilot study.
2008,
Pubmed
Shaw,
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
2013,
Pubmed
Shaw,
Ceritinib in ALK-rearranged non-small-cell lung cancer.
2014,
Pubmed
Shaw,
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
2016,
Pubmed
Shi,
CNS Metastases in Patients With Non-Small-Cell Lung Cancer and ALK Gene Rearrangement.
2016,
Pubmed
Solomon,
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
2014,
Pubmed
Solomon,
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
2016,
Pubmed
Sun,
ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.
2013,
Pubmed
Welsh,
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
2013,
Pubmed
Zhang,
Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.
2015,
Pubmed
